From GlobeNewswire: 2025-05-05 06:30:00

Integra LifeSciences Holdings Corporation reported first quarter revenues of $382.7 million, with a 3.7% increase on a reported basis and a 3.5% decrease on an organic basis compared to the prior year. GAAP earnings per diluted share were $(0.33), while adjusted earnings per diluted share were $0.41. Adjusted EBITDA for the quarter was $63.6 million.

The company’s Codman Specialty Surgical segment saw total revenues of $280.7 million, with reported growth of 9.4% and an organic decline of 1.1%. Neurosurgery sales declined 4.7%, while Instruments sales grew 15.1%. ENT reported revenue growth due to the Acclarent acquisition. Tissue Technologies segment had total revenues of $102.0 million, with a reported decline of 9.3% and an organic decline of 9.1%.

Integra remains focused on advancing its Compliance Master Plan, expanding its international portfolio, and improving supply reliability. The company appointed new leadership in key positions to drive accountability and execution. The balance sheet shows total balance sheet debt and net debt at $1.85 billion and $1.58 billion, respectively, with total liquidity of approximately $1.16 billion.

For the second quarter of 2025, Integra expects reported revenues in the range of $390 million to $400 million, with an adjusted EPS range of $0.40 to $0.45 per share. For the full year 2025, the company reaffirmed its revenue guidance ranges of $1.650 billion to $1.715 billion and adjusted EPS guidance of $2.19 to $2.29 per share. Adjusted EPS guidance includes estimates for the impact of new tariffs.

The company’s adjusted EBITDA for the first quarter of 2025 was $63.6 million, or 16.6% of revenue, compared to $71.8 million, or 19.5% of revenue, in the prior year. Adjusted net income for the first quarter of 2025 was $31.7 million, or $0.41 per diluted share, compared to $43.0 million, or $0.55 per diluted share, in the prior year.



Read more at GlobeNewswire:: Integra LifeSciences Reports First Quarter 2025 Financial